Roger Goldberg, MD
Urogynecology and Reconstructive Pelvic Surgery · Skokie, ILNPI 1285733139
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 78.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $26,350 and has fallen 79.3% since, to $5,447 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $928.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$42K
- Intuitive Surgical$6K
- Escala Medical Inc.$4K
- AbbVie$499
- Coloplast$434
- Medtronic$84
- plus $208 from 9 others
What the payments were for
- Consulting fees$9,63018%
- Speaking & faculty fees$26,23549%
- Travel & lodging$10,12519%
- Food & beverage$1,8383%
- Education$6,02711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 32 | $42,242 |
| Intuitive Surgical | 3 | $6,007 |
| Escala Medical Inc. | 1 | $4,380 |
| AbbVie | 4 | $499 |
| Coloplast | 4 | $434 |
| Medtronic | 5 | $84 |
| Axonics, Inc. | 1 | $39 |
| Astellas Pharma US Inc | 1 | $33 |
| 180 Medical, Inc. | 1 | $28 |
| Laborie Medical Technologies Corp. | 1 | $28 |
| Urovant Sciences Inc | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Convatec Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $15 |
| THD America, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PELVIC ORGAN PROLAPSE$12,600
- GENERAL - THERAPIES$9,838
- UPHOLD$9,000
- GENERAL FEMALE SUI$6,615
- Da Vinci Surgical System$6,000
- UPHOLD LITE$1,575
- ADVANTAGE$1,395
- ALTIS$327
- BOTOX$300
- SOLYX$262
- OZURDEX$107
- Advantage System$103
How this compares
$53,854 in reported general payments places this provider in the 95th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 67 | $66,059 |
| GemtesaVibegron | 39 | $35,007 |
| Methenamine Hippurate | 186 | $19,435 |
| Trospium Chloride ErTrospium Chloride | 94 | $14,494 |
| BotoxOnabotulinumtoxina | 14 | $9,699 |
| Trimethoprim | 161 | $8,774 |
| Estradiol | 119 | $6,888 |
| Solifenacin Succinate | 149 | $5,618 |
| Trospium Chloride | 27 | $1,720 |
| Oxybutynin Chloride ErOxybutynin Chloride | 59 | $1,251 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 81 | $1,069 |
| Cefpodoxime Proxetil | 18 | $720 |
| Cephalexin | 83 | $509 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 69 | $263 |
| Fluconazole | 15 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $33 | $66,05967 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $21 | $35,00739 claims |
| AbbVieBotox | $499 | $9,69914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
Other urogynecology and reconstructive pelvic surgery in Skokie
- Peter SandSkokie$185K
- Adam Gafni KaneSkokie$7K
- Nani MossSkokie$5K
- Sonia DuttaSkokie$2K
- Janet TomezskoSkokie$1K
- Ghazaleh Rostami NiaSkokie$735
- Cynthia BrincatSkokie$37
- Abraham ShashouaChicago$339K
- Akira GillinghamChicago$58K
- Kimberly KentonChicago$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.